mRNA-6007 / Moderna - LARVOL DELTA

Horizon 3 modalities have the potential to advance to first-in-human clinical trials by the end of 2027. (Investing News Network (INN)) - "mRNA-6007 (In vivo CAR-T): Designed to enable deep B-cell depletion for autoimmune conditions using a multiplexed mRNA approach with targeted lipid nanoparticles, the program aims to deliver mRNA into immune cells in vivo, enabling transient CAR expression and potential immune reset. The initial clinical focus is systemic lupus erythematosus (SLE) and other B cell mediated autoimmune diseases."

First-in-human • New trial • Immunology • Systemic Lupus Erythematosus